Relationship between angiotensin I blockade and antihypertensive properties of single doses of MK-421 and captopril in spontaneous and renal hypertensive rats

European Journal of Pharmacology

Volumn 76, Issue 2-3, 1981, Pages 167-176

  Sweet, Charles S ^a   Arbegast, Phyllis T ^a   Lee Gaul, S ^a   Blaine, Edward H ^a   Gross, Dennis M ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

2 Kidney Grollman; Angiotensin I; Captopril; Converting enzyme; MK 421; Pressor response; RHR Renal hypertensive rats; SHR

Indexed keywords

ANGIOTENSIN I [5 ISOLEUCINE]; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENALAPRIL MALEATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR SYSTEM; DRUG MECHANISM; ENDOCRINE SYSTEM; ENZYME INHIBITION; HYPERTENSION; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PRESSOR RESPONSE; RAT; RENOVASCULAR HYPERTENSION; SPONTANEOUSLY HYPERTENSIVE RAT;

ANGIOTENSIN I; ANGIOTENSINS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CAPTOPRIL; DIPEPTIDES; ENALAPRIL; HYPERTENSION; HYPERTENSION, RENAL; OLIGOPEPTIDES; PROLINE; RATS; RATS, INBRED STRAINS; TEPROTIDE;

EID: 0019777471     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/0014-2999(81)90498-2     Document Type: Article

References (34)

1. Effects of an orally effective converting enzyme inhibitor (YS-980) on renal function in dogs
2. The effects of captopril, propranolol and indomethacin on blood pressure and plasma renin activity in spontaenously hypertensive and normotensive rats
3. Contribution of the kidneys but not the adrenal glands to the acute antihypertensive effects of captopril in SH rats
4. Effects of chronic treatment with captopril (SQ 14,225), an orally active inhibitor of angiotensin I-converting enzyme, in spontaneously hypertensive rats
5. Long-term blockade of angiotensin formation in various normotensive and hypertensive rat models using converting enzyme inhibitor (SQ 14,225)
6. New tables for multiple comparisons with a control
7. Preventions of the development of spontaneous hypertension in rats by captopril (SQ 14,225)
8. Effects of continuous converting enzyme blockade on renovascular hypertension in the rat
9. Effect of N-[(S)-1-carboxy-3-phenylpropyl]-L-Ala-L-Pro and its ethyl ester (MK-421) on angiotensin converting enzyme in vitro and angiotensin I pressor response in vivo
10. Chronic blockade of angiotensin II formation during sodium deprivation
11. Hypotensive action of captopril and saralasin in intact and anephric spontaneously hypertensive rats
12. Blood pressure responses of conscious rats to intracerebroventricular and peripheral administration of the angiotensin converting enzyme inhibitor, captopril
13. Antihypertensive activity in rats of SQ 14,225, an orally active inhibitor of angiotensin converting enzyme
14. Vasodepressor property of the converting enzyme inhibitor captopril (SQ 14,225): the role of factors other than renin-angiotensin blockade in the rat
15. The effects of angiotensin I-converting enzyme inhibitors on arterial blood pressure and urinary sodium excretion. Role of the renal renin-angiotensin and kallikrein-kinin systems
16. Single-dose captopril administration in DOCA/salt rats: reduction of hypotensive effect of indomethacin
17. The effect of captopril on blood pressure and angiotensin I, II and III in sodium-depleted dogs: problems associated with the measurement of angiotensin II after inhibition of converting enzyme
18. Antihypertensive action of the orally active converting enzyme inhibitor (SQ 14,225) in spontneously hypertensive rats
19. The mechanism of bradykinin potentiation after inhibition of angiotensin-converting enzyme by SQ14,225 in conscious rabbits
20. A new class of angiotensin converting enzyme inhibitors
21. Chronic antihypertensive effects of captopril (SQ 14,225), an orally active angiotensin I-converting enzyme inhibitor, in conscious 2-kidney renal hypertensive rats
22. Captopril (SQ 14,225) (D-3-mercapto-2-methylpropanoyl-L-Proline): A novel orally active inhibitor of angiotensin-converting enzyme and active inhibitor of angiotensin-converting enzyme and antihypertensive agent
23. Effect of converting enzyme inhibitor (SQ 14,225) on myocardial hypertrophy in spontaneously hypertensive rats
24. The central and peripheral effects of captopril (SQ 14,225) on the arterial pressure of the spontaneously hypertensive rat
25. Captopril-induced changes in prostaglandin production
26. Antihypertensive activity of N-[(S)-1-ethoxycarbonyl)-3-phenylpropyl]-L-Ala-L-Pro (MK-421) an orally active converting enzyme inhibitor
27. Cardiovascular properties of antihypertensive drugs in a model of severe renal hypertension
28. Converting enzyme inhibitors and saralasin infusion in rats. Evidence for an additional vasodepressor property of converting enzyme inhibitor
29. Evidence that the acute hypotensive effect of captopril is not wholly explained by a reduction of plasma angiotensin II and its direct vasoconstrictor effect
30. Antihypertensive effects of the novel converting-enzyme inhibitor YS 980 ins spontaneously hypertensive rats
31. Central cardiovascular effects of SQ 14,225, an angiotensin-converting enzyme inhibitor in chlorolose anesthesized cats
32. Discrepancy between antihypertensive effect and angiotensin converting enzyme inhibition by captopril